allose profile

ID Source	ID
PubMed CID	439507
CHEMBL ID	1222152
CHEBI ID	4093
CHEBI ID	37690
CHEBI ID	17393
CHEBI ID	37742
SCHEMBL ID	60362
MeSH ID	M0042519

Synonym
CHEMBL1222152
ALL ,
CHEBI:4093 ,
ALLOSE ,
C01487
d-allose ,
allose, d-
579-36-2
nsc-144657
d-allopyranose ,
DB03989
BMSE000008
AKOS006272674
BMSE000808
BMSE001008
SCHEMBL60362
d-all
allopyranose
d-allopyranoside
allopyranoside
Q27106301
DTXSID201015878
d-allo-hexose
dtxcid501474033
chebi:37690
allo-hexose
chebi:17393
chebi:37742

Research Excerpts

Overview

Excerpt	Reference
"D-allose is a rare sugar that has been reported to up-regulate thioredoxin-interacting protein (TXNIP) expression and affect the production of intracellular reactive oxygen species (ROS). "	( Akimitsu, K; Haba, R; Ibuki, E; Izumori, K; Kakehi, Y; Matsuoka, Y; Sugimoto, M; Taoka, R; Tohi, Y; Yoshihara, A; Zhang, X, 2022)
"D-Allose is a rare cis-caprose with a wide range of physiological functions, which has a wide range of applications in medicine, food, and other industries. "	( Chen, Y; Dong, S; Duan, S; Li, Z; Ma, C; Wang, G; Wang, R; Wang, Y; Wu, Y, 2023)
"d-Allose is an aldohexose of the C3-epimer of d-glucose, existing in very small amounts in nature, called a rare sugar. "	( Kamitori, S, 2023)
"d-Allose is a low-calorie rare sugar with great application potential in the food and pharmaceutical industries. "	( Gao, X; Guan, L; Li, C; Liu, W; Lu, F; Qin, HM; Wang, F; Wang, J; Wei, M; Zhang, W, 2023)
"d-Allose is a rare sugar that has been reported to have some unique physiological effects."	( Ibaraki, M; Kinoshita, T; Kudomi, N; Nishiyama, Y; Tago, T; Toyohara, J; Wada, K; Yamamoto, H; Yamamoto, Y, 2019)
"D-Allose is a rare sugar, can be used as an ingredient in a range of foods and dietary supplements, has alimentary activities, especially excellent anti-cancer effects and used in assisting cancer chemotherapy and radiotherapy, etc. "	( Du, K; Gao, L; Li, C; Lin, H; Lin, J; Ren, Y, 2020)
"D‑allose is a rare sugar which has been shown to have growth inhibitory effects in several kinds of malignancies. "	( Hossain, A; Kadowaki, N; Kamitori, K; Kanaji, N; Katagi, A; Noguchi, C; Tokuda, M, 2018)
"D-Allose is a rare monosaccharide, which rarely appears in the natural environment. "	( Chen, J; Chen, Z; Guang, C; Mu, W; Zhang, T; Zhang, W, 2018)
"D-allose is a monosaccharide. "	( Asaga, T; Chujo, K; Iwanaga, Y; Ono, J; Taie, S; Ueki, M, 2008)
"D-Allose is a monosaccharide (C-3 epimer of glucose) distributed rarely in nature; because of its scarcity and cost, the biological effect has hardly been studied."	( Chung, BC; Jo, MJ; Kim, MO; Kim, SH; Lee, HY; Naha, N, 2008)
"d-Allose is a novel anti-tumor monosaccharide that causes cell growth inhibition, specifically of the cancer cells, by inducing the tumor suppressor gene thioredoxin interacting protein (TXNIP). "	( Dong, Y; Horii, M; Kamitori, K; Sanada, K; Sui, L; Tokuda, M; Yamaguchi, F, 2008)
"D-allose is an aldo-hexose present in nature that recently has been demonstrated to inhibit production of inflammatory mediators in septic kidneys."	( Asaga, T; Miyawaki, Y; Shirakami, G; Tokuda, M; Ueki, M; Ueno, M, 2012)

Effects

Excerpt	Reference
"D-Allose has an 80% sweetness relative to table sugar but is ultra-low calorie and non-toxic and is thus an ideal candidate to take the place of table sugar in food products."	( Chen, J; Chen, Z; Guang, C; Mu, W; Zhang, T; Zhang, W, 2018)
"D-allose has a considerable potential as a new anticancer agent in those patients."	( Hoshikawa, H; Hosokawa, T; Kamitori, K; Mitani, T; Mori, N; Mori, T; Tokuda, M; Tsukamoto, I; Yamaguchi, F, 2009)
"D-Allose has been demonstrated to exert many physiological functions."	( Akimitsu, K; Hoshino, K; Miyake, M; Miyazaki, R; Suzuki, M; Takao, K, 2022)
"d-allose has the biological activity to protect against ischemia-reperfusion injury, however, the underlying mechanism remains unclear."	( Fei, Z; Fu, YH; Gao, DK; Gou, MR; Luo, YW; Zhang, L; Zhang, M, 2023)
"D-allose has shown great promise for combating tumor cells with no side effects, especially in combination with first-line drugs; however, its potential for cancer therapy has not been comprehensively investigated in vitro or in vivo."	( Ganjavi, M; Khajeh, S; Panahi, G; Razban, V; Tahami, SM; Zare, M, 2023)
"D-Allose has an 80% sweetness relative to table sugar but is ultra-low calorie and non-toxic and is thus an ideal candidate to take the place of table sugar in food products."	( Chen, J; Chen, Z; Guang, C; Mu, W; Zhang, T; Zhang, W, 2018)
"As d-allose has no known side effects on normal cells, the combination of d-allose and 5-FU might be a potent candidate for cancer therapy."	( Dong, Y; Horii, M; Kamitori, K; Sanada, K; Sui, L; Tokuda, M; Yamaguchi, F, 2008)
"D-allose has a considerable potential as a new anticancer agent in those patients."	( Hoshikawa, H; Hosokawa, T; Kamitori, K; Mitani, T; Mori, N; Mori, T; Tokuda, M; Tsukamoto, I; Yamaguchi, F, 2009)
"D-allose has attracted a great deal of attention in recent years due to its many pharmaceutical activities, which include anti-cancer, anti-tumor, anti-inflammatory, anti-oxidative, anti-hypertensive, cryoprotective, and immunosuppressant activities. "	( Lim, YR; Oh, DK, 2011)

Treatment

Excerpt	Reference
"D-allose treatment inhibited the proliferation of U251MG and U87MG cells in a dose-dependent manner (3-50 mM)."	( Akimitsu, K; Fujimori, T; Izumori, K; Kanda, T; Miyake, K; Nishiyama, A; Ogawa, D; Ohsaki, H; Rahman, A; Shibayama, Y; Suzuki, K; Tamiya, T; Ye, J, 2023)
"D-allose treatment significantly suppressed the MPO activity and the number of MPO-positive cells compared with those in the vehicle group, suggesting that treatment with D-allose can reduce the infiltration of leukocytes into the ischemic tissue."	( Fei, Z; Gao, D; Kawai, N; Lu, F; Nakamura, T; Tamiya, T, 2013)
"D-allose treatment of isolated islet culture prior to transplantation restored islet function and increased successful transplant rate. "	( Akamoto, S; Asano, E; Hossain, A; Kashiwagi, H; Noguchi, C; Okano, K; Sui, L; Suzuki, Y; Tokuda, M, 2016)
"D-allose-treated cells."	( Colby-Germinario, S; Germinario, RJ; Manuel, S; Pratt, SE, 1994)
"Co-treatment of D-allose and the antioxidant L-glutathione canceled the D-allose-induced reduction in cell viability and intracellular ROS elevation."	( Akimitsu, K; Haba, R; Ibuki, E; Izumori, K; Kakehi, Y; Matsuoka, Y; Sugimoto, M; Taoka, R; Tohi, Y; Yoshihara, A; Zhang, X, 2022)
"Treatment of D-allose also significantly decreased the number of COX-2-positive cells and microglial activation in the ischemic tissue."	( Fei, Z; Gao, D; Kawai, N; Lu, F; Nakamura, T; Tamiya, T, 2013)

allose is involved in 2 pathway(s), involving a total of 9 unique proteins and 17 unique compounds

Role	Description
antioxidant	A substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
D-allose
allopyranose
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
D-Allulose Degradation	6	9
D-allose degradation	3	8

Assay ID	Title	Year	Journal	Article
AID500279	Ratio of Kcat to Km for Neisseria meningitidis lgtC	2006	Nature chemical biology, Dec, Volume: 2, Issue:12	Using substrate engineering to harness enzymatic promiscuity and expand biological catalysis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	15 (9.93)	18.7374
1990's	10 (6.62)	18.2507
2000's	42 (27.81)	29.6817
2010's	59 (39.07)	24.3611
2020's	25 (16.56)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

allose

Cross-References

Synonyms (28)

Research Excerpts

Overview

Effects

Treatment

Roles (1)

Drug Classes (2)

Pathways (2)

Bioassays (1)

Research

Studies (151)

Study Types

Research Highlights

Safety/Toxicity (3)

Dosage (1)

Interactions (1)

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	5 (3.27%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	148 (96.73%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Condition	Relationship Strength	Studies
Acute Kidney Failure	low	1
Acute Kidney Injury	low	1
Acute Kidney Insufficiency	low	1
Acute Renal Failure	low	1
Acute Renal Injury	low	1
Acute Renal Insufficiency	low	1
Allergy, Egg	low	1
Alloxan Diabetes	low	1
Anoxemia	low	2
Anoxia	low	2
Anterior Cerebral Circulation Infarction	low	1
Anterior Choroidal Artery Infarction	low	1
Anterior Circulation Brain Infarction	low	1
Anterior Circulation Infarction, Brain	low	1
Anterior Circulation Transient Ischemic Attack	low	1
Astrocytoma, Grade IV	low	1
Benign Neoplasms	low	4
Bladder Cancer	low	1
Bladder Neoplasms	low	1
Bladder Tumors	low	1
Blood Pressure, High	low	1
Body Weight	low	3
Brain Edema	low	1
Brain Infarct	low	1
Brain Infarction	low	1
Brain Infarction, Anterior Circulation	low	1
Brain Infarction, Posterior Circulation	low	1
Brain Infarction, Venous	low	1
Brain Ischemia	low	1
Brain Stem Ischemia, Transient	low	1
Brain Stem Transient Ischemic Attack	low	1
Brain Swelling	low	1
Brain TIA	low	1
Brainstem Ischemia, Transient	low	1
Brainstem Transient Ischemic Attack	low	1
Cancer	low	4
Cancer of Bladder	low	1
Cancer of Head	low	3
Cancer of Head and Neck	low	3
Cancer of Liver	low	4
Cancer of Lung	low	2
Cancer of Mouth	low	3
Cancer of Neck	low	3
Cancer of Ovary	low	1
Cancer of Pancreas	low	1
Cancer of Prostate	low	2
Cancer of the Bladder	low	1
Cancer of the Head	low	3
Cancer of the Head and Neck	low	3
Cancer of the Liver	low	4
Cancer of the Lung	low	2
Cancer of the Mouth	low	3
Cancer of the Neck	low	3
Cancer of the Ovary	low	1
Cancer of the Pancreas	low	1
Cancer of the Prostate	low	2
Cancer, Hepatocellular	low	4
Carcinoma, Epidermoid	low	3
Carcinoma, Hepatocellular	low	2
Carcinoma, Lewis Lung	low	1
Carcinoma, Non-Small Cell Lung	low	2
Carcinoma, Non-Small-Cell Lung	low	2
Carcinoma, Planocellular	low	3
Carcinoma, Squamous	low	3
Carcinoma, Squamous Cell	low	3
Carotid Circulation Transient Ischemic Attack	low	1
Cerebral Edema	low	1
Cerebral Edema, Cytotoxic	low	1
Cerebral Edema, Vasogenic	low	1
Cerebral Infarct	low	1
Cerebral Infarction	low	1
Cerebral Infarction, Left Hemisphere	low	1
Cerebral Infarction, Middle Cerebral Artery	low	2
Cerebral Infarction, Right Hemisphere	low	1
Cerebral Ischemia	low	1
Cerebral Ischemia, Transient	low	1
Cerebral, Left Hemisphere, Infarction	low	1
Cerebral, Right Hemisphere, Infarction	low	1
Cirrhosis	low	1
Condition, Preneoplastic	low	1
Conditions, Preneoplastic	low	1
Crescendo Transient Ischemic Attacks	low	1
Cytotoxic Brain Edema	low	1
Cytotoxic Cerebral Edema	low	1
Deficiency, Oxygen	low	2
Diabetes Mellitus	low	1
Diabetes Mellitus, Experimental	low	1
Disease Models, Animal	low	5
Disease Resistance	low	1
Dyskinesia Syndromes	low	2
Egg Allergy	low	1
Egg Hypersensitivity	low	1
Elevated Cholesterol	low	1
Embolic Infarction, Middle Cerebral Artery	low	2
Embolus, Middle Cerebral Artery	low	2
Encephalopathy, Ischemic	low	1
Etat Marbre	low	2
Experimental Diabetes Mellitus	low	1
Fibrosis	low	1
Giant Cell Glioblastoma	low	1
Glioblastoma	low	1
Glioblastoma Multiforme	low	1
Head and Neck Cancer	low	3
Head and Neck Neoplasm	low	3
Head and Neck Neoplasms	low	3
Head Cancer	low	3
Head Neoplasm	low	3
Head Neoplasms	low	3
Head, Neck Neoplasms	low	3
Hepatic Cancer	low	4
Hepatic Neoplasms	low	4
Hepatocellular Cancer	low	4
Hepatocellular Carcinoma	low	2
Hepatoma	low	2
High Cholesterol Levels	low	1
Hypercholesteremia	low	1
Hypercholesterolemia	low	1
Hypersensitivity, Egg	low	1
Hypertension	low	1
Hypoxemia	low	2
Hypoxia	low	2
Infarction, Anterior Cerebral Circulation	low	1
Infarction, Anterior Circulation, Brain	low	1
Infarction, Brain, Anterior Circulation	low	1
Infarction, Brain, Posterior Circulation	low	1
Infarction, Cerebral	low	1
Infarction, Cerebral, Left Hemisphere	low	1
Infarction, Cerebral, Right Hemisphere	low	1
Infarction, Left Hemisphere, Cerebral	low	1
Infarction, Middle Cerebral Artery	low	2
Infarction, Posterior Circulation, Brain	low	1
Infarction, Right Hemisphere, Cerebral	low	1
Infections, Plasmodium	low	1
Inflammation	low	1
Injury, Ischemia-Reperfusion	low	15
Injury, Reperfusion	low	15
Innate Inflammatory Response	low	1
Intracranial Edema	low	1
Intraocular Pressure	low	1
Ischemia-Reperfusion Injury	low	15
Ischemia, Cerebral	low	1
Ischemic Attack, Transient	low	1
Ischemic Encephalopathy	low	1
Kidney Diseases	low	1
Kidney Failure, Acute	low	1
Kidney Insufficiency, Acute	low	1
Left Hemisphere, Cerebral Infarction	low	1
Left Hemisphere, Infarction, Cerebral	low	1
Left Middle Cerebral Artery Infarction	low	2
Leucocythaemia	low	2
Leucocythemia	low	2
Leukemia	low	2
Liver Cancer	low	4
Liver Cancer, Adult	low	2
Liver Cell Carcinoma	low	2
Liver Cell Carcinoma, Adult	low	2
Liver Diseases	low	1
Liver Dysfunction	low	1
Liver Neoplasms	low	4
Lung Cancer	low	2
Lung Neoplasms	low	2
Malaria	low	1
Malignancy	low	4
Malignant Neoplasms	low	4
Malignant Tumor of Urinary Bladder	low	1
Marsh Fever	low	1
MCA Infarct	low	2
MCA Infarction	low	2
Middle Cerebral Artery Circulation Infarction	low	2
Middle Cerebral Artery Embolic Infarction	low	2
Middle Cerebral Artery Embolus	low	2
Middle Cerebral Artery Infarction	low	2
Middle Cerebral Artery Occlusion	low	2
Middle Cerebral Artery Stroke	low	2
Middle Cerebral Artery Syndrome	low	2
Middle Cerebral Artery Thrombosis	low	2
Middle Cerebral Artery Thrombotic Infarction	low	2
Mouth Cancer	low	3
Mouth Neoplasms	low	3
Movement Disorder Syndromes	low	2
Movement Disorders	low	2
Neck Cancer	low	3
Neck Neoplasm	low	3
Neck Neoplasms	low	3
Neoplasia	low	4
Neoplasm	low	4
Neoplasms	low	4
Neoplasms, Benign	low	4
Neoplasms, Bladder	low	1
Neoplasms, Head	low	3
Neoplasms, Head and Neck	low	3
Neoplasms, Hepatic	low	4
Neoplasms, Liver	low	4
Neoplasms, Lung	low	2
Neoplasms, Mouth	low	3
Neoplasms, Neck	low	3
Neoplasms, Oral	low	3
Neoplasms, Ovarian	low	1
Neoplasms, Pancreatic	low	1
Neoplasms, Prostate	low	2
Neoplasms, Prostatic	low	2
Neoplasms, Pulmonary	low	2
Neoplasms, Upper Aerodigestive Tract	low	3
Non-Small Cell Lung Cancer	low	2
Non-Small Cell Lung Carcinoma	low	2
Non-Small-Cell Lung Carcinoma	low	2
Nonsmall Cell Lung Cancer	low	2
Occlusion, Middle Cerebral Artery	low	2
Oral Cancer	low	3
Oral Neoplasms	low	3
Ovarian Cancer	low	1
Ovarian Neoplasms	low	1
Ovary Cancer	low	1
Ovary Neoplasms	low	1
Oxygen Deficiency	low	2
Paludism	low	1
Pancreas Cancer	low	1
Pancreas Neoplasms	low	1
Pancreatic Cancer	low	1
Pancreatic Neoplasms	low	1
Plasmodium Infections	low	1
Posterior Choroidal Artery Infarction	low	1
Posterior Circulation Brain Infarction	low	1
Posterior Circulation Infarction, Brain	low	1
Posterior Circulation Transient Ischemic Attack	low	1
Precancerous Conditions	low	1
Preneoplastic Condition	low	1
Preneoplastic Conditions	low	1
Prostate Cancer	low	2
Prostate Neoplasms	low	2
Prostatic Cancer	low	2
Prostatic Neoplasms	low	2
Proteinuria	low	1
Pulmonary Cancer	low	2
Pulmonary Neoplasms	low	2
Remittent Fever	low	1
Renal Failure, Acute	low	1
Renal Insufficiency, Acute	low	1
Reperfusion Damage	low	15
Reperfusion Injury	low	15
Resistance, Disease	low	1
Retinal Diseases	low	2
Right Hemisphere, Cerebral Infarction	low	1
Right Hemisphere, Infarction, Cerebral	low	1
Right Middle Cerebral Artery Infarction	low	2
Sensitivity and Specificity	low	1
Squamous Cell Carcinoma	low	3
Status Marmoratus	low	2
Streptozocin Diabetes	low	1
Streptozotocin Diabetes	low	1
Stroke, Middle Cerebral Artery	low	2
Subcortical Infarction	low	1
Thrombosis, Middle Cerebral Artery	low	2
Thrombotic Infarction, Middle Cerebral Artery	low	2
TIA (Transient Ischemic Attack)	low	1
Transient Ischemic Attack	low	1
Transient Ischemic Attack, Anterior Circulation	low	1
Transient Ischemic Attack, Brain Stem	low	1
Transient Ischemic Attack, Brainstem	low	1
Transient Ischemic Attack, Carotid Circulation	low	1
Transient Ischemic Attack, Posterior Circulation	low	1
Transient Ischemic Attack, Vertebrobasilar Circulation	low	1
Transient Ischemic Attacks, Crescendo	low	1
Tumors	low	4
UADT Neoplasm	low	3
UADT Neoplasms	low	3
Upper Aerodigestive Tract Neoplasm	low	3
Upper Aerodigestive Tract Neoplasms	low	3
Urinary Bladder Cancer	low	1
Urinary Bladder Neoplasms	low	1
Vasogenic Brain Edema	low	1
Vasogenic Cerebral Edema	low	1
Venous Infarction, Brain	low	1
Vertebrobasilar Circulation Transient Ischemic Attack	low	1

Article	Year
Thermal degradation of agar: Mechanism and toxicity of products. Food chemistry, Oct-30, Volume: 264	2018
D-allose ameliorates cisplatin-induced nephrotoxicity in mice. The Tohoku journal of experimental medicine, Volume: 228, Issue: 3	2012
Acute and sub-chronic toxicity of D-allose in rats. Bioscience, biotechnology, and biochemistry, Volume: 74, Issue: 7	2010
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Article	Year
D-allose and D-psicose reinforce the action of metronidazole on trichomonad. Parasitology research, Volume: 110, Issue: 4	2012
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Article	Year
Additive antitumour effect of D‑allose in combination with cisplatin in non-small cell lung cancer cells. Oncology reports, Volume: 39, Issue: 3	2018
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

allose

Cross-References

Synonyms (28)

Research Excerpts

Overview

Effects

Treatment

Roles (1)

Drug Classes (2)

Pathways (2)

Bioassays (1)

Research

Studies (151)

Study Types

Related Drugs (336)

Related Conditions (274)

Research Highlights

Safety/Toxicity (3)

Dosage (1)

Interactions (1)